Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
One-fifth of the Japanese population is positive for HLA-A26, but few peptides are available as potential cancer vaccines for HLA-A26-positive cancer patients. The objective of this study was to identify peptide vaccine candidates for HLA-A26-positive cancer patients. The HLA-A*2601-crossbinding activity of 24 peptides currently under clinical trial as vaccines for HLA-A2, -A24, or HLA-A3 supertype-positive cancer patients was evaluated by stabilization assay. Three peptides with HLA-A2-binding activity could bind the HLA-A*2601 molecule. These three peptides induced HLA-A26-restricted cytotoxic T lymphocytes from HLA-A*2601-, -A*2602-, or -A*2603-positive prostate cancer patients against HLA-A*2601- and HLA-A*2603-positive cancer cells in CD8-dependent and peptide-specific manners. In addition, one peptide with HLA-A24-binding activity could bind to HLA-A*2601 and induced HLA-A26-restricted cytotoxic T lymphocytes from HLA-A*2601-, -A*2602-, or -A*2603-positive prostate cancer patients against HLA-A*2603-positive cancer cells. These results may provide novel information for the development of a peptide-based cancer vaccine for HLA-A26-positive patients.
Niu
Yamei
Y
Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Terasaki
Yasunobu
Y
Komatsu
Nobukazu
N
Noguchi
Masanori
M
Shichijo
Shigeki
S
Itoh
Kyogo
K
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D015234:HLA-A Antigens / Q000032:analysis / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000032:analysis / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019496:Cancer Vaccines; D015234:HLA-A Antigens; C039683:HLA-A*26 antigen; D015789:HLA-A2 Antigen; D059871:HLA-A24 Antigen
J Immunother. 2000 Sep-Oct;23(5):511-8
11001544
Oncogene. 2001 Sep 6;20(39):5562-9
11571656
Int J Oncol. 2004 Feb;24(2):337-47
14719110
Int J Oncol. 2009 Feb;34(2):529-36
19148489
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6933-43
16203785
Cancer Res. 1995 Oct 1;55(19):4248-52
7671230
Cancer Immunol Immunother. 2009 Nov;58(11):1877-85
19330328
J Gen Virol. 2007 Jul;88(Pt 7):1986-1991
17554032
Clin Cancer Res. 2004 Feb 1;10(3):1112-20
14871991
J Immunol. 1995 Jan 15;154(2):685-93
7529283
Immunol Res. 1996;15(3):179-90
8902575
J Cell Biol. 1989 Dec;109(6 Pt 1):2575-87
2687284
Bone Marrow Transplant. 2007 Jul;40(2):165-74
17530010
Tissue Antigens. 2000 Apr;55(4):296-302
10852380
Cancer Res. 1999 Aug 15;59(16):4056-63
10463607
Hum Immunol. 1996 Feb;45(2):79-93
8882405
Immunogenetics. 1999 Nov;50(3-4):213-9
10602881
Cancer Res. 2001 Mar 1;61(5):2038-46
11280764
J Med Virol. 2009 Jul;81(7):1232-40
19475615
Clin Cancer Res. 2004 Feb 1;10(3):929-37
14871969